Consensus Seres Therapeutics, Inc.

Stocks

MCRB

US81750R2013

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 12:36:07 2026-09-10 EDT			5-day change	1st Jan Change
5.110 ^USD	-3.22%		-9.75%	-65.79%

08-13	Seres Therapeutics Files $300 Million Mixed Shelf	MT
08-05	Seres Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Evolution of the Average Target: Seres Therapeutics, Inc.

Evolution of the Target Price: Seres Therapeutics, Inc.

Changes in Analyst Recommendations: Seres Therapeutics, Inc.

d40a0.5NgFGqPZBqxXh3lswqblR-Dp5DVbhH20xroqZDMGdE0.rqBRUfmOfOkOzCgqicnSLLWDlANo8TzS8YtiIVJeEASgiUduk61f-SL_MA~20e14e476176d9fe68aab40099c1a332

Analysts' recommendations: Seres Therapeutics, Inc.

06-23	HC Wainwright Initiates Seres Therapeutics at Buy With $12 Price Target	MT
25-05-08	Seres Therapeutics Shares Fall After Downgrade From Chardan	MT
25-05-08	Chardan Downgrades Seres Therapeutics to Neutral From Buy, Adjusts Price Target to $6 From $25	MT
24-10-24	JPMorgan Downgrades Seres Therapeutics to Underweight	MT
24-06-07	Canaccord Genuity Adjusts Price Target on Seres Therapeutics to $10 From $15, Maintains Buy Rating	MT
24-06-07	Oppenheimer Downgrades Seres Therapeutics to Perform From Outperform, Removes $4 Price Target	MT
24-06-07	Chardan Adjusts PT on Seres Therapeutics to $1.25 From $6 on Heels of Announced MoU With Nestle for Sale of VOWST Assets; Maintains Buy Rating	MT
24-05-09	Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating	MT
24-05-09	Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating	MT
24-03-06	Oppenheimer Adjusts Seres Therapeutics Price Target to $5 From $9, Maintains Outperform Rating	MT
24-03-06	Chardan Cuts Price Target on Seres Therapeutics to $8 From $10 on Higher Expected Sharecount Dilution, Keeps Buy Rating	MT
24-01-16	Oppenheimer Trims Seres Therapeutics Price Target to $9 From $10, Maintains Outperform Rating	MT
23-11-03	Goldman Sachs Adjusts Price Target on Seres Therapeutics to $1.25 From $4, Maintains Sell Rating	MT
23-11-03	Oppenheimer Adjusts Seres Therapeutics Price Target to $10 From $12, Maintains Outperform Rating	MT
23-04-28	Chardan Cuts Price Target on Seres Therapeutics to $10 From $12, Keeps Buy Rating	MT
23-04-21	JPMorgan Starts Seres Therapeutics at Neutral	MT
23-03-21	Canaccord Genuity Adjusts Price Target on Seres Therapeutics to $15 From $11, Maintains Buy Rating	MT
23-03-08	Canaccord Genuity Lowers Price Target on Seres Therapeutics to $11 From $17, Maintains Buy Rating	MT
22-09-07	Piper Sandler Adjusts Price Target on Seres Therapeutics to $9 From $7, Reiterates Overweight Rating	MT
22-08-04	Chardan Capital Lowers Seres Therapeutics Price Target to $12 From $16, Maintains Buy Rating	MT
22-08-04	Oppenheimer Adjusts Seres Therapeutics' Price Target to $12 From $13, Maintains Outperform Rating	MT
22-05-23	Piper Sandler Lowers Seres Therapeutics' to $7 From $32, Overweight Rating Kept	MT
22-03-02	Oppenheimer Adjusts Seres Therapeutics Price Target to $13 From $16, Maintains Outperform Rating	MT
21-07-23	Seres Therapeutics : Oppenheimer Adjusts Seres Therapeutics PT to $18 From $36, Maintains Outperform Rating	MT
21-07-23	Seres Therapeutics : Chardan Adjusts Price Target on Seres Therapeutics to $16 From $30 After Drug Disappoints in Study, Maintains Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Objective/dr gap
SERES THERAPEUTICS, INC.	-	+221.97%
WUXI APPTEC CO., LTD.		+20.78%
ARGENX SE		+16.43%
INSMED INCORPORATED		+55.42%
WUXI BIOLOGICS (CAYMAN) INC.		+18.16%
BIONTECH SE		+21.45%
GENMAB A/S		+14.99%
PHARMAESSENTIA CORPORATION		+3.89%
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.		+28.57%
EXELIXIS, INC.		-7.96%
Average		+39.37%
Weighted average by Cap.		+20.59%